Scholar Rock Holding (STU:2QK) 5-Year EBITDA Growth Rate : 4.60% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Scholar Rock Holding 5-Year EBITDA Growth Rate?

Scholar Rock Holding's EBITDA per Share for the three months ended in Mar. 2024 was €-0.56.

During the past 3 years, the average EBITDA Per Share Growth Rate was 10.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Scholar Rock Holding was 10.10% per year. The lowest was -30.30% per year. And the median was -4.50% per year.

Competitive Comparison of Scholar Rock Holding's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Scholar Rock Holding's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scholar Rock Holding's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Scholar Rock Holding's 5-Year EBITDA Growth Rate falls into.

Scholar Rock Holding 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Scholar Rock Holding (STU:2QK) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Scholar Rock Holding 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Scholar Rock Holding's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Scholar Rock Holding (STU:2QK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scholar Rock Holding Corp (STU:2QK) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SRRK:USA

Address

301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142

Website

https://www.scholarrock.com

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is Apitegroma which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Scholar Rock Holding (STU:2QK) Headlines

No Headlines